TY - JOUR
T1 - Patient and physician factors associated with participation in cervical and uterine cancer trials
T2 - An NRG/GOG247 study
AU - Brooks, Sandra E.
AU - Carter, Randy L.
AU - Plaxe, Steven C.
AU - Basen-Engquist, Karen M.
AU - Rodriguez, Michael
AU - Kauderer, James
AU - Walker, Joan L.
AU - Myers, Tashanna K.N.
AU - Drake, Janet G.
AU - Havrilesky, Laura J.
AU - Van Le, Linda
AU - Landrum, Lisa M.
AU - Brown, Carol L.
N1 - Publisher Copyright:
© 2015 Elsevier Inc.
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Purpose The aim of this study was to identify patient and physician factors related to enrollment onto Gynecologic Oncology Group (GOG) trials. Methods Prospective study of women with primary or recurrent cancer of the uterus or cervix treated at a GOG institution from July 2010 to January 2012. Logistic regression examined probability of availability, eligibility and enrollment in a GOG trial. Odds ratios (OR) and 95% confidence intervals (CI) for significant (p < 0.05) results reported. Results Sixty institutions, 781 patients, and 150 physicians participated, 300/780 (38%) had a trial available, 290/300 had known participation status. Of these, 150 women enrolled (59.5%), 102 eligible did not enroll (35%), 38 (13%) were ineligible. Ethnicity and specialty of physician, practice type, data management availability, and patient age were significantly associated with trial availability. Patients with > 4 comorbidities (OR 4.5; CI 1.7-11.8) had higher odds of trial ineligibility. Non-White patients (OR 7.9; CI 1.3-46.2) and patients of Black physicians had greater odds of enrolling (OR 56.5; CI 1.1-999.9) in a therapeutic trial. Significant patient therapeutic trial enrollment factors: belief trial may help (OR 76.9; CI 4.9-> 1000), concern about care if not on trial (OR12.1; CI 2.1-71.4), pressure to enroll (OR.27; CI 0.12-.64), caregiving without pay (OR 0.13; CI.02-.84). Significant physician beliefs were: patients would not do well on standard therapy (OR 3.6; CI 1.6-8.4), and trial would not be time consuming (OR 3.3; CI 1.3-8.1). Conclusions Trial availability, patient and physician beliefs were factors identified that if modified could improve enrollment in cancer cooperative group clinical trials.
AB - Purpose The aim of this study was to identify patient and physician factors related to enrollment onto Gynecologic Oncology Group (GOG) trials. Methods Prospective study of women with primary or recurrent cancer of the uterus or cervix treated at a GOG institution from July 2010 to January 2012. Logistic regression examined probability of availability, eligibility and enrollment in a GOG trial. Odds ratios (OR) and 95% confidence intervals (CI) for significant (p < 0.05) results reported. Results Sixty institutions, 781 patients, and 150 physicians participated, 300/780 (38%) had a trial available, 290/300 had known participation status. Of these, 150 women enrolled (59.5%), 102 eligible did not enroll (35%), 38 (13%) were ineligible. Ethnicity and specialty of physician, practice type, data management availability, and patient age were significantly associated with trial availability. Patients with > 4 comorbidities (OR 4.5; CI 1.7-11.8) had higher odds of trial ineligibility. Non-White patients (OR 7.9; CI 1.3-46.2) and patients of Black physicians had greater odds of enrolling (OR 56.5; CI 1.1-999.9) in a therapeutic trial. Significant patient therapeutic trial enrollment factors: belief trial may help (OR 76.9; CI 4.9-> 1000), concern about care if not on trial (OR12.1; CI 2.1-71.4), pressure to enroll (OR.27; CI 0.12-.64), caregiving without pay (OR 0.13; CI.02-.84). Significant physician beliefs were: patients would not do well on standard therapy (OR 3.6; CI 1.6-8.4), and trial would not be time consuming (OR 3.3; CI 1.3-8.1). Conclusions Trial availability, patient and physician beliefs were factors identified that if modified could improve enrollment in cancer cooperative group clinical trials.
KW - Cervical cancer trials
KW - Clinical trial enrollment
KW - Gynecologic Oncology Group
KW - Minority enrollment
KW - NRG Oncology
KW - Patient and physician factors
KW - Uterine cancer trials
UR - http://www.scopus.com/inward/record.url?scp=84931575421&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84931575421&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2015.04.033
DO - 10.1016/j.ygyno.2015.04.033
M3 - Article
C2 - 25937529
AN - SCOPUS:84931575421
SN - 0090-8258
VL - 138
SP - 101
EP - 108
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 1
ER -